Initial Direct Laryngoscopy Versus TORS Alone for Unknown Primary HPV+ Oropharyngeal Squamous Cell Carcinoma
Otolaryngology–Head and Neck Surgery · 2025
DOI: 10.1002/ohn.1256 ↗At a glance
Vergleichsstudie in Otolaryngology–Head and Neck Surgery, 2025. Written by Alexander J Jones and 8 co-authors. Institution: Department of Otolaryngology-Head and Neck Surgery, Clevleand Clinic, Cleveland, Ohio, USA. Major MEDLINE topics: Oropharyngeal Neoplasms, Neoplasms, Unknown Primary, Laryngoscopy, Robotic Surgical Procedures. Cited 1 times so far (Crossref); 35 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Objective
This study aims to determine whether initial direct laryngoscopy with biopsy (DLBx) before transoral robotic surgery (TORS) has differences in perioperative outcomes, tumor identification, and oncologic outcomes for unknown primary oropharyngeal human papillomavirus (HPV+) squamous cell carcinoma (OPSCC). Study Design A retrospective cohort.
Setting
A single‐institution, tertiary referral center.
Methods
All patients with HPV+ squamous cell carcinoma and unknown primary (cTx) undergoing TORS from 2014 to 2024 were collected. Patients receiving DLBx + TORS versus TORS alone were compared.
Results
A total of 57 patients had no evidence of primary disease on exam, flexible laryngoscopy, and PET/CT imaging, of which 20 (35%) underwent TORS + neck dissection without previous DLBx. Primary tumor was identified on 38% of DLBx and 74% of combined primary and secondary TORS. Only 19% of all cTx patients remained true unknown primary on final pathology (pT0). Demographics and perioperative courses were similar between the two groups. TORS was able to detect primary tumor in the majority of tongue base disease (83%). There were no differences in overall primary tumor size (median 0.8 vs. 1.0 cm), nodal burden, tumor, node, metastasis classification, adjuvant treatment, or 5‐year disease‐free survival.
Conclusion
Initial DLBx for unknown primary HPV+ OPSCC has similar perioperative and oncologic outcomes to performing initial TORS alone and may unnecessarily delay definitive surgery and add healthcare costs. Level of Evidence IV.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Otolaryngology-Head and Neck Surgery, Clevleand Clinic, Cleveland, Ohio, USA.
- Department of Otolaryngology-Head and Neck Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Department of ENT and Skull Base Surgery, Barrow Neurological Institute, Phoenix, Arizona, USA.
ORCID profiles: Alexander J Jones, Peyton Z Robinson, Deborah X Xie, Janice L Farlow, Jessica A Yesensky, Avinash V Mantravadi, Michael W Sim
Cite
APA
Jones, A. J., Robinson, P. Z., Xie, D. X., Farlow, J. L., Moore, M. G., Campbell, D. A., Yesensky, J. A., Mantravadi, A. V., & Sim, M. W. (2025). Initial Direct Laryngoscopy Versus TORS Alone for Unknown Primary HPV+ Oropharyngeal Squamous Cell Carcinoma. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.1256
Vancouver
Jones AJ, Robinson PZ, Xie DX, Farlow JL, Moore MG, Campbell DA, et al. Initial Direct Laryngoscopy Versus TORS Alone for Unknown Primary HPV+ Oropharyngeal Squamous Cell Carcinoma. Otolaryngology–Head and Neck Surgery. 2025. doi:10.1002/ohn.1256
BibTeX
@article{Jones2025,
author = {Jones, Alexander J and Robinson, Peyton Z and Xie, Deborah X and Farlow, Janice L and Moore, Michael G and Campbell, David A and Yesensky, Jessica A and Mantravadi, Avinash V and Sim, Michael W},
title = {Initial Direct Laryngoscopy Versus TORS Alone for Unknown Primary HPV+ Oropharyngeal Squamous Cell Carcinoma},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2025},
doi = {10.1002/ohn.1256}
}
EUVIMED